New Safety Measures for Epilepsy Drug After Rare Severe Reactions

The U.S. Food and Drug Administration (FDA) has issued a safety warning regarding a rare but serious drug reaction associated with specific antiseizure medications. The warning focuses on levetiracetam and clobazam, noting that these medicines can cause a potentially life-threatening condition if not diagnosed and treated promptly.

The reaction is identified as Drug Reaction with Eosinophilia and Systemic Symptoms, commonly referred to as DRESS. According to the FDA, this hypersensitivity reaction can begin as a rash but may rapidly progress to cause injury to internal organs, necessitate hospitalization, or lead to death.

Affected Medications and Regulatory Actions

The FDA safety communication, issued on November 28, 2023, specifically names several brand-name versions of these medications. For levetiracetam, the affected products include Keppra, Keppra XR, Elepsia XR, and Spritam.

For clobazam, the warning applies to Onfi and Sympazan. In response to these risks, the FDA is requiring manufacturers to update the prescribing information and patient Medication Guides for these drugs.

The regulatory requirements differ slightly by medication. For levetiracetam products, a new warning must be added to the Warnings and Precautions section of the prescribing information, as previous descriptions of these symptoms were less prominent.

For clobazam products, the FDA is requiring a new warning specifically dedicated to DRESS. While symptoms related to this risk were previously described more generally in other sections of the clobazam prescribing information, the new requirement ensures a more specific alert.

Identifying DRESS Symptoms

DRESS is characterized by a combination of systemic symptoms and organ involvement. The FDA notes that the reaction may include the following:

• Fever
• Rash
• Swollen lymph nodes
• Injury to internal organs, including the liver, kidneys, lungs, heart, or pancreas

A critical detail highlighted by the FDA is that early symptoms, such as fever or swollen lymph nodes, can be present even in cases where a rash is not visible. This underscores the importance of monitoring for systemic signs of the reaction regardless of whether skin changes have occurred.

Medical Context and Patient Safety

While the FDA describes this hypersensitivity reaction as serious, it also emphasizes that the occurrence of DRESS is rare. The primary objective of the updated labeling is to ensure that healthcare providers and caregivers can identify the condition early enough to provide life-saving treatment.

The need for immediate medical attention is paramount once symptoms appear, as the progression from a simple rash to systemic organ failure can happen quickly. The updated Medication Guides are intended to provide patients and caregivers with the necessary information to recognize these warning signs.